source
- FDA approves Zenocutuzumab for NRG1 fusion-positive advanced cholangiocarcinomaThe U.S. Food and Drug Administration has granted approval for zenocutuzumab-zbco, marketed as Bizengri, to treat adult patients with NRG1 fusion‑positive advanced, unresectable or metastatic chola…
- Trump reportedly plans to dismiss FDA Commissioner Marty MakaryMultiple media outlets report that President Donald Trump is considering removing FDA Commissioner Marty Makary from his post. The reports say the decision has not been finalized and could still be…